Swissmedic expands on existing multilateral agreement
This article was originally published in RAJ Devices
Executive Summary
A meeting between the national drug and device authorities of Switzerland ( Swissmedic), Australia ( Therapeutic Goods Administration), Canada ( Health Canada) and Singapore ( Health Sciences Authority) has served to intensify the existing collaboration among the countries1. The principal focus of a new co-operative agreement signed by the various agencies is on initiatives in the fields of marketing authorisation and market surveillance. It applies to both medical devices and pharmaceuticals2.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.